Cipher receives Health Canada approval of CIP-Fenofibrate
The notification came after the Federal Court of Canada advised the Company it would dismiss the legal proceedings brought by Fournier-Pharma Inc. and Laboratoires Fournier S.A. related to the second of two patent issues. The dismissal cleared the path for Health Canada to issue final approval for CIP-Fenofibrate. Cipher announced in January 2006 that it received final approval for CIP-Fenofibrate in the United States from the U.S. Food and Drug Administration.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.